Loading clinical trials...
Loading clinical trials...
A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Conditions
Interventions
SPH4336
Locations
9
United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
City of Hope
Duarte, California, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
University of Michigan
Ann Arbor, Michigan, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Start Date
August 31, 2023
Primary Completion Date
October 4, 2024
Completion Date
October 31, 2024
Last Updated
June 13, 2025
Lead Sponsor
Shanghai Pharma Biotherapeutics USA Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions